Literature DB >> 8835629

Glycosylation improves the priming effect exerted by recombinant human granulocyte colony-stimulating factor (lenograstim) on human neutrophil superoxide production.

E Decleva1, R Cramer, G Zabucchi.   

Abstract

The role of glycosylation in modulating the activity of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) on polymorphonuclear leukocytes (PMNs) was investigated. We addressed this study by comparing the effects of lenograstim (glycosylated rHuG-CSF) and its deglycosylated counterpart on superoxide production by PMNs on fibronectin. When the triggering activity of the cytokine was evaluated, no O2- release was elicited from neutrophils treated with either preparation of rHuG-CSF. Instead, a clear potentiation of both fMLP- and TNF-induced respiratory burst was produced by preincubating the cells with rHuG-CSF. Such effect was found to be significantly increased when glycosylated versus deglycosylated preparation was used, leading to the conclusion that the sugar moiety of the molecule could be of importance in improving the priming activity exerted by rHuG-CSF on PMN metabolic response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8835629

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  4 in total

Review 1.  Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor.

Authors:  M W N Harbord; D J B Marks; A Forbes; S L Bloom; R M Day; A W Segal
Journal:  Aliment Pharmacol Ther       Date:  2006-08-15       Impact factor: 8.171

Review 3.  Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 4.  Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference?

Authors:  M Höglund
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.